ASLAN Pharmaceuticals (ASLN) Competitors $0.60 0.00 (0.00%) (As of 12/19/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends ASLN vs. ALZN, FRTX, MAAQ, APVO, LIXT, ALBT, GHSI, OGEN, PRTG, and CELZShould you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Alzamend Neuro (ALZN), Fresh Tracks Therapeutics (FRTX), Mana Capital Acquisition (MAAQ), Aptevo Therapeutics (APVO), Lixte Biotechnology (LIXT), Avalon GloboCare (ALBT), Guardion Health Sciences (GHSI), Oragenics (OGEN), Portage Biotech (PRTG), and Creative Medical Technology (CELZ). These companies are all part of the "pharmaceutical products" industry. ASLAN Pharmaceuticals vs. Alzamend Neuro Fresh Tracks Therapeutics Mana Capital Acquisition Aptevo Therapeutics Lixte Biotechnology Avalon GloboCare Guardion Health Sciences Oragenics Portage Biotech Creative Medical Technology Alzamend Neuro (NASDAQ:ALZN) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings. Which has better valuation & earnings, ALZN or ASLN? Alzamend Neuro has higher earnings, but lower revenue than ASLAN Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$9.95MN/AN/AASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92-0.03 Does the MarketBeat Community believe in ALZN or ASLN? ASLAN Pharmaceuticals received 194 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 63.49% of users gave ASLAN Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAlzamend NeuroOutperform Votes6100.00% Underperform VotesNo VotesASLAN PharmaceuticalsOutperform Votes20063.49% Underperform Votes11536.51% Which has more risk and volatility, ALZN or ASLN? Alzamend Neuro has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Does the media favor ALZN or ASLN? In the previous week, Alzamend Neuro had 5 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 5 mentions for Alzamend Neuro and 0 mentions for ASLAN Pharmaceuticals. Alzamend Neuro's average media sentiment score of 0.05 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the media. Company Overall Sentiment Alzamend Neuro Neutral ASLAN Pharmaceuticals Neutral Do analysts recommend ALZN or ASLN? Alzamend Neuro currently has a consensus target price of $32.00, suggesting a potential upside of 2,782.88%. ASLAN Pharmaceuticals has a consensus target price of $76.00, suggesting a potential upside of 12,566.67%. Given ASLAN Pharmaceuticals' higher probable upside, analysts clearly believe ASLAN Pharmaceuticals is more favorable than Alzamend Neuro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ALZN or ASLN more profitable? Alzamend Neuro's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A N/A -568.88% ASLAN Pharmaceuticals N/A -8,454.87%-121.60% Do insiders & institutionals believe in ALZN or ASLN? 49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 10.6% of Alzamend Neuro shares are owned by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryASLAN Pharmaceuticals beats Alzamend Neuro on 7 of the 13 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get ASLAN Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASLN vs. The Competition Export to ExcelMetricASLAN PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23M$6.57B$5.02B$9.08BDividend YieldN/A3.09%4.87%4.20%P/E Ratio-0.0310.55135.0817.16Price / Sales0.10194.011,120.30115.67Price / CashN/A57.1640.5837.88Price / Book-0.095.104.754.78Net Income-$44.22M$151.51M$118.50M$225.60M7 Day PerformanceN/A-2.13%-1.85%-1.21%1 Month PerformanceN/A-3.13%11.28%3.09%1 Year Performance-83.59%11.54%29.91%16.48% ASLAN Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASLNASLAN Pharmaceuticals1.0687 of 5 stars$0.60flat$76.00+12,566.7%N/A$1.23M$12M-0.0330ALZNAlzamend Neuro2.6331 of 5 stars$1.25+9.6%$35.00+2,700.0%-86.8%$4.86MN/A0.004News CoverageFRTXFresh Tracks TherapeuticsN/A$0.75+3.4%N/A-7.5%$4.48M$8.01M0.0020Positive NewsMAAQMana Capital AcquisitionN/A$0.55+19.6%N/A-53.4%$4.47MN/A0.001Gap UpHigh Trading VolumeAPVOAptevo Therapeutics2.0521 of 5 stars$8.73-10.0%$10,952.00+125,352.5%-100.0%$4.45M$3.11M0.0050LIXTLixte BiotechnologyN/A$1.97+2.1%N/A-5.7%$4.43MN/A-1.103ALBTAvalon GloboCare0.3355 of 5 stars$4.05-1.7%N/A-53.6%$4.41M$1.26M0.005GHSIGuardion Health SciencesN/A$3.22-2.1%N/A-38.0%$4.35M$12.25M0.6610Gap DownOGENOragenicsN/A$0.36-4.0%N/AN/A$4.34M$40,000.000.005News CoveragePRTGPortage Biotech1.3857 of 5 stars$4.11-0.5%N/A-74.3%$4.32MN/A-0.106CELZCreative Medical Technology0.5905 of 5 stars$2.45flatN/A-55.6%$4.29M$10,000.000.005Positive NewsGap Up Related Companies and Tools Related Companies ALZN Alternatives FRTX Alternatives MAAQ Alternatives APVO Alternatives LIXT Alternatives ALBT Alternatives GHSI Alternatives OGEN Alternatives PRTG Alternatives CELZ Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ASLN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ASLAN Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
